Blue Bell, PA – According to filings with the U.S. Securities and Exchange Commission, Seneca Therapeutics is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Hussey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Seneca Therapeutics
Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (SVV-001), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.

To learn more about Seneca Therapeutics, visit http://senecatherapeutics.com/

Contact:
James Hussey, Chief Executive Officer
484-883-9725
jhussey@senecatherapeutics.com
https://www.linkedin.com/in/james-hussey-5b511148/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved